MIRM

Analyst Note: Mirum Pharmaceuticals, Inc. (MIRM)

Date: 2026-06-13 Sector: Healthcare | Industry: Biotechnology (Rare & Orphan)

1. Structural Readiness

• Conservative Entry: $110.08
• Current Price: $107.13
• Extension: -2.7% vs. conservative entry
• Breakout Level: $110.08 (Conservative) / $110.08 (Aggressive/Confirmation)
• ATR Context: High (4.4% at breakout; 4.4% current). This volatility profile sits within the historical "sweet spot" (4–6%) for structural quality, indicating sufficient momentum potential without the extreme instability associated with >8% ATR.

Structural Assessment:

2. Thesis Layer

• Primary Secular Theme: Biotech & GLP-1 → Rare & Orphan (Tier Direct, High Confidence).
• Thesis Weighting: Mirum is a direct beneficiary of the secular shift toward high-value, targeted therapies for ultra-rare genetic diseases. The company has successfully transitioned from a single-product reliance (LIVMARLI) to a diversified rare disease platform.
• Additional Context: The company is positioned at the intersection of orphan drug development and commercial execution. The "Rare & Orphan" theme is particularly potent here due to the regulatory incentives (priority review, orphan designation) and the high pricing power inherent in treating ultra-rare conditions with no alternatives. The company's role is that of a Growth Leader within this niche, leveraging a "broadening" pipeline to capture multiple market segments simultaneously.

3. Business Overview

Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for rare and orphan diseases. As of June 2026, the company operates a three-pillar commercial business supported by a robust late-stage pipeline.

• Commercial Portfolio: The company currently markets three approved medicines:
• LIVMARLI® (maralixibat): For Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC). Management notes "robust adoption in PFIC, particularly in adult patients," driven by successful education initiatives among liver providers.
• CHOLBAM® (cholic acid): For bile acid synthesis disorders.
• CTEXLI® (chenodiol): For cholesterol gallstone disease.
• Financial Performance: As of Q1 2026, the commercial business demonstrated strong unit economics. Management reported a cash contribution margin in the mid-50s percent and cash flow from operations of approximately $2 million.
• Guidance: In the May 6, 2026 earnings call, management raised full-year revenue guidance to $660 million to $680 million, reflecting the commercial ramp of existing products and the anticipation of new approvals.
• Pipeline & Strategic Partnerships:
• Zilurgisertib (FOP): In April 2026, Mirum entered an agreement with Incyte to commercialize zilurgisertib for Fibrodysplasia Ossificans Progressiva (FOP). The FDA has accepted the NDA for priority review with a PDUFA date of September 26, 2026. Management expects a launch by year-end if approved. FOP is an ultra-rare disease with ~300 patients in the U.S. and ~900 globally.
• Volixibat (PSC): Topline results from the VISTAS Phase 2b trial in Primary Sclerosing Cholangitis (PSC) were announced in May 2026. Management expects to submit an NDA in the second half of 2026, with potential approval and launch in the first half of 2027.
• Brelovitug (HDV): Evaluated in the global AZURE program. Topline results for registration-enabling trials (AZURE-1 and AZURE-4) are expected in the second half of 2026, potentially supporting a BLA submission in the first half of 2027.
• Other Pipeline: The VANTAGE trial in PBC is expected to complete enrollment in H2 2026. The EXPAND study is complete with topline data expected in Q4 2026.

4. Archetype and Conviction

• Archetype: Growth Leader.
• Rationale: Mirum fits the Growth Leader archetype due to its transition from a single-product biotech to a multi-product commercial entity with accelerating revenue and positive cash flow. The company is executing a "platform" strategy, moving from a single asset (LIVMARLI) to a portfolio of 3 approved drugs and a pipeline of 4+ late-stage assets.
• Conviction Stack:
• Thesis Strength: High. The "Rare & Orphan" theme is structural and durable.
• Evidence Quality: Strong. The company has provided specific, quantified guidance ($660M-$680M revenue) and clear regulatory milestones (PDUFA dates, NDA submission timelines).
• Structural Quality: High. The ATR of 4.4% indicates healthy volatility suitable for a growth setup. The "swing" pivot strength suggests the stock is in a defined trend.
• Setup Readiness: Partial. The coil is forming. The price is consolidating near the breakout level ($110.08) but has not yet confirmed the move. The -2.7% extension is a shallow pullback, suggesting underlying strength, but the breakout is the necessary trigger.
• Rerating Potential: Significant. The market is currently pricing in the commercial success of LIVMARLI, but the upcoming PDUFA decision for Zilurgisertib (Sept 2026) and the NDA submission for Volixibat (H2 2026) represent binary catalysts that could expand the total addressable market (TAM) valuation multiple.

5. Invalidations, Strengtheners, and Gaps

• Strengtheners:
• A close above $110.08 would confirm the breakout, signaling the start of the next leg up.
• Positive data readouts from the VANTAGE (PBC) or EXPAND trials.
• Confirmation of the September 2026 PDUFA approval for Zilurgisertib.
• Gaps in Evidence:
• Long-term Cash Runway: While Q1 2026 showed positive cash flow ($2M), the evidence base does not explicitly detail the total cash balance or burn rate trajectory beyond the current quarter. The sustainability of positive cash flow as the company scales commercial operations for new assets (Zilurgisertib, Volixibat) is a key variable not fully quantified in the provided snippets.
• Reimbursement Dynamics: There is no specific evidence regarding payer coverage or reimbursement rates for the new assets (Zilurgisertib, Volixibat), which are critical for realizing the $200M+ peak sales potential management has cited.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: high Key evidence: Raised full-year revenue guidance to $660M-$680M; FDA accepted NDA for Zilurgisertib with Sept 2026 PDUFA; Positive cash flow from operations in Q1 2026; Robust adoption of LIVMARLI in adult PFIC. Key risks: FDA rejection or delay of Zilurgisertib NDA; Failure to achieve expected reimbursement rates for new assets; Execution risk in commercializing multiple new products simultaneously. Expected path: Management expects to launch Zilurgisertib by year-end 2026 if approved, followed by NDA submission for Volixibat in H2 2026 and potential approval in H1 2027, expanding the commercial portfolio. Expected horizon: 6 to 12 months for the primary catalyst (Zilurgisertib approval) to resolve. Failure mode to watch: A close below $90.00, which would invalidate the structural setup and suggest a breakdown in the growth narrative.